Int J Infect Dis
. 2020 May 10;S1201-9712(20)30333-7.
doi: 10.1016/j.ijid.2020.05.026. Online ahead of print.
Use of Anakinra in Severe COVID-19: A Case Report
Giovanni Filocamo 1 , Davide Mangioni 2 , Paola Tagliabue 3 , Stefano Aliberti 4 , Giorgio Costantino 5 , Francesca Minoia 6 , Alessandra Bandera 7
Affiliations
- PMID: 32437934
- DOI: 10.1016/j.ijid.2020.05.026
Abstract
Coronavirus Disease 19 is a global healthcare emergency with high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID-19 successfully treated with IL-1 receptor antagonist (anakinra).
Keywords: Anakinra; Biologic; COVID-19; IL-1; Treatment.
Copyright ? 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.